IP Library › Granted Patent US 8,394,914
Granted Patent B2
US 8,394,914 · App. 12/460,655 · Granted Mar 12, 2013

Functional polyglycolide nanoparticles derived from unimolecular micelles

Inventors: Gregory L. Baker (Haslett, MI); Milton R. Smith, III (East Lansing, MI); Erin Vogel (Midland, MI)
Assignee: Board of Trustees of Michigan State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,914
App. No.
12/460,655
Granted
Mar 12, 2013
Kind
B2
Abstract

Poly(glycolide) polymers are disclosed. The polymers generally include a glycolide-based polymer backbone that includes one or more functional groups such as alkynyl groups, hydrophilic organic triazole groups, hydrophobic organic triazole groups (also including amphiphilic organic triazole groups), di-triazole organic crosslinking groups, and triazole-substituted drug derivatives. The alkynyl groups provide reactive sites for further functionalization of the polymer, for example by reaction with azide derivatives. The polymers can further encapsulate a drug for delivery to a patient (i.e., as compared to drug derivatives that are covalently attached to the polymer). The polymers can be in the form of thermodynamically stable unimolecular micelles or crosslinked nanoparticles. The polymer compositions are completely biodegradable and hold great potential for use in biomedical applications.

Claims (19)

1. A poly(glycolide) polymer comprising: a triazole reaction product of

(a) an alkynyl glycolide according to Formula III

(b) an azide-substituted hydrophilic organic compound; and,

(c) optionally one or more of an azido organic crosslinker, an azide-substituted hydrophobic organic compound, an azide-substituted liquid crystal mesogen, an azide-substituted dye, and an azide-substituted drug;

wherein:

(i) R 1 comprises one or more moieties selected from a hydrogen, an alkyl group, and an alkynyl group;

(ii) R 2 comprises an alkynyl group;

(iii) R comprises a terminal group;

(iv) x ranges from 0 to less than 1; and,

(v) n ranges from about 10 to about 1000.

2. The poly(glycolide) polymer of claim 1 , wherein the alkynyl group comprises 3 to 12 carbon atoms.

3. The poly(glycolide) polymer of claim 1 , wherein the azide-substituted hydrophilic organic compound comprises a compound selected from the group consisting of an azide-substituted polyoxyalkylene, an azide-substituted organic amine, an azide-substituted carboxylic acid, an azide-substituted carboxylate salt, an azide-substituted alkyl polyoxyalkylene, an azide-substituted ketone, an azide-substituted alcohol, an azide-substituted ester, and combinations thereof.

4. The poly(glycolide) polymer of claim 1 , wherein the polymer is in the form of a unimolecular micelle having (i) a diameter of about 50 nm or less as measured by dynamic light scattering in aqueous solution with (ii) a substantially hydrophilic exterior and a substantially hydrophobic interior.

5. The poly(glycolide) polymer of claim 4 , wherein the unimolecular micelle further-comprises an encapsulated drug within the interior.

6. The poly(glycolide) polymer of claim 4 , wherein the triazole reaction product comprises moieties resulting from the reaction of the alkynyl glycolide according to Formula III and the azide-substituted drug.

7. The poly(glycolide) polymer of claim 1 , wherein: the triazole reaction product comprises moieties resulting from the reaction of the alkynyl glycolide according to Formula III and the azido organic crosslinker, the polymer is in the form of an intramolecularly crosslinked nanoparticle having (i) a diameter of about 35 nm or less as measured by dynamic light scattering in aqueous solution with (ii) a substantially hydrophilic exterior and a substantially hydrophobic interior.

8. The poly(glycolide) polymer of claim 7 , wherein the crosslinked nanoparticle further comprises an encapsulated drug within the interior.

9. The poly(glycolide) polymer of claim 7 , wherein the triazole reaction product comprises moieties resulting from the reaction of the alkynyl glycolide according to Formula III and the azide-substituted drug.

10. A plurality of crosslinked nanoparticles according to claim 7 , wherein the plurality of crosslinked nanoparticles has a distribution of crosslinking degrees selected to control the rate of release of an encapsulated component or a covalently bound component in the plurality of crosslinked nanoparticles.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: BAKER, GREGORY L.; SMITH, III, MILTON R.; VOGEL, ERIN
To: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
Reel/Frame 023077/0725 →
Continuity (4)
Continuation In Part 12229544 · Aug 25, 2008
Provisional Application 61135679 · Jul 23, 2008
Provisional Application 60966042 · Aug 24, 2007
Related Publication 20090325292A1 · Dec 31, 2009